Context Therapeutics (CNTX) Preferred Stock Liabilities (2020 - 2021)
Context Therapeutics' (CNTX) quarterly Preferred Stock Liabilities came in at $21.1 million in Q3 2021, up 65726.95% year-on-year from N/an in Q3 2020, and up 43.87% quarter-over-quarter from $14.6 million in Q2 2021.
Context Therapeutics (CNTX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Context Therapeutics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $21.1 million for Q3 2021.
- Preferred Stock Liabilities for Q3 2021 came in at $21.1 million, up 65726.95% year-over-year; the trailing twelve-month figure through Sep 2021 was $21.1 million (up 65726.95% YoY), and the FY2020 annual result was $7.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $21.1 million for Q3 2021 at Context Therapeutics, up from $14.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $21.1 million in Q3 2021 to a low of $32000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Context Therapeutics | 166.57 Mn | 166.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 21.06 Mn |
| Jun 30, 2021 | 14.64 Mn |
| Mar 31, 2021 | 9.99 Mn |
| Dec 31, 2020 | 7.77 Mn |
| Sep 30, 2020 | 32,000.00 |